Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

Neratinib HER Mutation Basket Study (SUMMIT)

This is an open-label, non-randomized, multicenter, multinational, Phase 2 study exploring the efficacy and safety of neratinib as monotherapy or in combination with other therapies in patients with ERBB mutation-positive or EGFR gene-amplified solid tumors.
Bladder, Colon, Esophageal, Gastric/Gastroesophageal, Neuro-Oncology, Ovarian, Urologic, Uterine
Phase II
Adults
Chemotherapy - cytotoxic, Hormonal Therapy, Mol. targeted/Immunotherapy/Biologics
Fulvestrant, Neratinib (HKI-272), Paclitaxel, Trastuzumab (Herceptin)
Mayer, Ingrid
National
Vanderbilt University
06-02-2014
Treatment
VICCMD1403
NCT01953926

Eligibility

18 Years
BOTH
NO
Inclusion Criteria:

Histologically confirmed cancers for which no curative therapy exists.

Documented HER2 mutation.

Pediatric patients (at least 12 but less than 18 years of age at signing of informed consent) may be recruited in the Fibrolamellar Carcinoma cohort.



Exclusion Criteria:

Prior treatment with any pan-HER tyrosine kinase inhibitor (eg, lapatinib, afatinib, dacomitinib, neratinib).

Patients who are receiving any other anticancer agents.

Symptomatic or unstable brain metastases.

Women who are pregnant or breast-feeding.

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: